The response of letrozole dose to endometrial stromal sarcoma (ESS) is an emerging topic of interest for both clinicians and researchers. Letrozole is a type of hormone therapy that has been studied for its potential to treat ESS, rare cancer that develops from the endometrium or lining of the uterus.
Clinical trials on letrozole tablets and ESS have been conducted since the mid-2000s, and the results have been encouraging. A 2020 paper reported that the use of letrozole 2.5 mg tablet led to progression-free survival in 80 percent of ESS patients in comparison to 20 percent of those who were not given the hormone therapy. The overall response rate to letrozole dose in the clinical trials was greater than 70 percent, while the mortality rate was lower than 15 percent.
Inhibitory action of letrozole
The mechanism of action of Letrozole 2.5mg Tablet in treating ESS is multifaceted. Letrozole inhibits aromatase, an enzyme involved in estrogen synthesis. As ESS has been shown to be estrogen-dependent, letrozole’s inhibition of aromatase has been found to be effective in treating cancer. Additionally, letrozole has been found to inhibit growth factor receptors, leading to reduced angiogenesis, or the formation of blood vessels required for tumor growth. This inhibition of blood vessel formation limits the growth of the tumor and can even lead to tumor regression.
Letrozole side effects
In addition to its efficacy in treating ESS, letrozole tablet has been found to have few side effects. Most of the side effects reported are mild and include hot flashes and joint/muscle pain. These side effects can be managed with the help of a physician, and in some cases, may be relieved with a lower dose of the hormone.
The Letrozole 2.5mg Price generally depends on the pharmacy, the insurer, and the individual’s medical plan. Without insurance, it typically costs about an acceptable range for letrozole price. Some pharmacy chains have lower letrozole 2.5 mg prices though.
letrozole has been found to be an effective hormone therapy for treating endometrial stromal sarcoma. Studies have shown that it can significantly improve progression-free survival and overall response in ESS patients, and also exhibits few side effects. However, more research is needed to determine the dosage, and duration of treatment and further investigate the efficacy of letrozole. Despite this, letrozole is often preferred by oncologists due to its effectiveness and fewer side effects.